18 November 2022


Dear Colleague,

Fréderic Mouret, president and CEO of Protomed SA, is a seasoned European medical device entrepreneur. In a recent interview with me, he shared how his medical device development accelerator (Protomed SA) helped Bypass Solution SASU develop a side-to-end anastomosis device used in minimally invasive iliofemoral artery reconstruction and close a $3 millions dollar investment to go to the next phase.

Read the full interview here.
 

Karim Mouneimne: On June 9th, 2022, we heard some good news regarding Bypass Solution, which won an innovation award given by the Marseille Hospital group, APM, and the Marseille University Technology Transfer Office, SATT. I believe Bypass Solution is currently developing a side-to-end anastomosis device for iliofemoral artery reconstruction and you are the lead R&D group in this development. Could you please tell us a little bit more about Bypass Solution?

Fréderic Mouret: Bypass Solution is developing an End-to-side anastomosis device for vascular access and bypass. It was founded in October 2020. I am the CEO of this company. This startup company is relying on Protomed to do the R&D. With my support and the support of all our knowledge at Protomed, we are helping Bypass Solution grow into the next phases of device. The company has been funded by a family office based in Singapore since the beginning, and we just closed a round for €1.4 million Euros in dilutive and €1.6 million Euros in non dilutive financing. This funding will help us go to First-In-Man (FIM) with the technology, and that already a great achievement.

Karim Mouneimne: This is exciting news - €3 million in financing for a startup company! That is great.

Fréderic Mouret: Thank you.

Karim Mouneimne: Congratulations, it was probably a lot of hard work to get to this point. Was it your intention to bring the company to a First-In-Man? Has this always been the strategy?

Fréderic Mouret: Yes, It is definitely the strategy of the company. We want to bring it at least to First-In-Man, and then market the bypass part of the device. What we also want to do, is to develop our technology as a platform that can be used in various cardiovascular surgeries. For instance, we know that we can use this solution for bypass, not only for Fem-Pop (femoro-popliteal bypass), but also for aorto-iliac bypass and other vascular bypass.

Moreover, we think that this technology could be really beneficial for arterio-venous fistulas, anastomosis of cardiac support devices and why not for access of large port devices in the cardiovascular area, like TAVI devices. So definitely our goal is to focus on bypass, but also offer our technology to other areas in the cardiovascular space.

Has ViVitro helped with your work?

We conducted some tests at ViVitro Labs in Marseille to see where we were in terms of the leak proof quality of the anastomosis. It was interesting, the work we've done with you. Finally, we went to a concept that was working. We had a design and new patents. We did this first trial, which was really beneficial because it allowed us to find an investor to fund the development and create the company.

In the past two years, we have been focusing on completing the device proof of concept. Now, we have two patents on the design. We are working on new patents for the delivery systems, and we are starting work on the design output, and the design freeze of the device which we target in 12 to 18 months, and potentially go to the First-In-Man in the next three years.

Read the full interview here.
 

Read other Cardiovascular Pioneer interviews here.

Sales team Doug Bigrigg, Jérémie Decressac and our agents around the world continue to organize video conferences to discuss project needs. Please contact them today to find solutions that advance your R&D projects.

On behalf of my team, I wish you and your family good health.

Sincerely,